Previous 10 | Next 10 |
Xeris Pharmaceuticals (NASDAQ: XERS ) has priced a 9M-share public offering at $4.15 each. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Gainers : Rexahn Pharmaceuticals (NASDAQ: REXN ) +85% . More news on: Rexahn Pharmaceuticals, Inc., Sprint Corporation, Genprex, Inc., Stocks on the move, , Read more ...
CHICAGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has commenced an ...
Xeris Pharmaceuticals (NASDAQ: XERS) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We are including IQVIA scripts for Gvoke and glucagon below for the week ended 1/31/2020. Please note that these numbers were affected by ...
Cellect Biotechnology (NASDAQ: APOP ) +141% on new patents . More news on: Cellect Biotechnology Ltd., Apellis Pharmaceuticals, Inc., Advaxis, Inc., Stocks on the move, Read more ...
Gainers: XERS +21.1% . OTCQB:KNWN +11.6% . MCHP +4.5% . CEI +4.1% . ACOR +3.7% . More news on: Xeris Pharmaceuticals, Inc., Know Labs, Inc., Microchip Technology Incorporated, Stocks on the move, , News on ETFs Read more ...
Thinly traded micro cap Xeris Pharmaceuticals (NASDAQ: XERS ) is up 19% after hours in response to positive results from the in-clinic portion of a Phase 2 clinical trial evaluating ready-to-use (RTU) glucagon for the prevention of hypoglycemia (low blood sugar) in adults wit...
Results show a mini dose (150 µg) of RTU glucagon prevents Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a clinical research setting Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging it...
Of all the new science coming in through ASH 2019, one of the most important abstracts is this one from Roche (RHHBY). Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Recept...
All subjects successfully self-administered a mini dose of RTU glucagon Rebound hypoglycemia observed more frequently in the placebo arm and with oral glucose tablet use Subcutaneous RTU glucagon is safe and well-tolerated Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specia...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Xeris Pharmaceuticals Inc. Website:
The Dow Jones index closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern aro...
2024-05-10 10:00:12 ET David Amsellem from Piper Sandler issued a price target of $3.00 for XERS on 2024-05-10 08:29:00. The adjusted price target was set to $3.00. At the time of the announcement, XERS was trading at $1.8469. The overall price target consensus is at $6....
Q1 2024 Total Revenue of $40.6M – up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M Ended Q1 with $87.4M in cash, cash equivalents, and short-term investments, lowered borrowing rate of Hayfin debt by 2.05% Entered into a worldwide ...